The complement system as another target for inhibition in septic patients: Should we implement this treatment or wait for the evidence?

Critical Care Medicine

Volumn 40, Issue 3, 2012, Pages 988-990

  Lesur, Olivier ^a,b   Hermans, Cedric ^a,b  

^a CENTRE HOSPITALIER UNIVERSITAIRE DE SHERBROOKE   (Canada)

^b CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

C1 esterase inhibitor; complement; sepsis, survival

Indexed keywords

ACTIVATED PROTEIN C; BRADYKININ; COMPLEMENT COMPONENT C1S INHIBITOR; HEPARIN; PROTEINASE;

COMPLEMENT SYSTEM; DRUG MECHANISM; DRUG MEGADOSE; EDITORIAL; ENZYME INHIBITION; FIBRINOLYSIS; GRAFT REJECTION; HUMAN; MORTALITY; MULTIPLE ORGAN FAILURE; PRIORITY JOURNAL; SEPSIS; TREATMENT OUTCOME;

COMPLEMENT C1 INHIBITOR PROTEIN; FEMALE; HUMANS; MALE; SEPSIS;

EID: 84857552468     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e31823c898c     Document Type: Editorial

References (22)

1. Igonin AA, Protsenko DN, Galstyan GM, et al: C1-esterase inhibitor infusion increases survival rates for patients with sepsis. Crit Care Med 2012;40:770-777
2. Hack CE, Ogilvie AC, Eisele B, et al: C1-inhibitor substitution therapy in septic shock and in the vascular leak syndrome induced by high doses of interleukin-2. Intensive Care Med 1993;19:S19-S28
3. Hack CE, Ogilvie AC, Eisele B, et al: Initial studies on the administration of C1-esterase inhibitor to patients with septic shock or with a vascular leak syndrome induced by interleukin-2 therapy. Prog Clin Biol Res 1994;388:335-357
4. Caliezi C, Zeerleder S, Redondo M, et al: C1-inhibitor in patients with severe sepsis and septic shock: Beneficial effect on renal dysfunction. Crit Care Med 2002;30:1722-1728
5. Horstick G, Berg O, Heimann A, et al: Application of C1-esterase inhibitor during reperfusion of ischemic myocardium: Doserelated beneficial versus detrimental effects. Circulation 2001;104:3125-3131
6. Oikonomopoulou K, Ricklin D, Ward PA, et al: Interactions between coagulation and complementtheir role in inflammation. Semin Immunopathol 2012;34:151-165.
7. Younger JG, Bracho DO, Chung-Esaki HM, et al: Complement activation in emergency department patients with severe sepsis. Acad Emerg Med 2010;17:353-359
8. Hack CE, Nuijens JH, Felt-Bersma RJ, et al: Elevated plasma levels of the anaphylatoxins C3a and C4a are associated with a fatal outcome in sepsis. Am J Med 1989;86:20-26
9. Bosmann M, Ward PA: Role of c3, c5 and anaphylatoxin receptors in acute lung injury and in sepsis. Adv Exp Med Biol 2012;946:147-159
10. Oehmcke S, Herwald H: Contact system activation in severe infectious diseases. J Mol Med (Berl) 2010;88:121-126
11. Madeddu P, Emanueli C, El-Dahr S: Mechanisms of disease: The tissue kallikrein-kinin system in hypertension and vascular remodeling. Nat Clin Pract Nephrol 2007;3:208-221
12. Davis AE 3rd: The pathophysiology of hereditary angioedema. Clin Immunol 2005;114:3-9
13. Kaplan AP: Enzymatic pathways in the pathogenesis of hereditary angioedema: The role of C1 inhibitor therapy. J Allergy Clin Immunol 2010;126:918-925
14. Davis AE 3rd, Lu F, Mejia P: C1 inhibitor, a multi-functional serine protease inhibitor. Thromb Haemost 2010;104:886-893
15. Kalter ES, Daha MR, ten Cate JW, et al: Activation and inhibition of Hageman factordependent pathways and the complement system in uncomplicated bacteremia or bacterial shock. J Infect Dis 1985;151:1019-1027
16. Nuijens JH, Eerenberg-Belmer AJ, Huijbregts CC, et al: Proteolytic inactivation of plasma C1-inhibitor in sepsis. J Clin Invest 1989;84:443-450
17. Leid RW, Ballieux BE, van der Heijden I, et al: Cleavage and inactivation of human C1 inhibitor by the human leukocyte proteinase, proteinase 3. Eur J Immunol 1993;23:2939-2944
18. Zuraw BL: Clinical practice. Hereditary angioedema. N Engl J Med 2008;359:1027-1036
19. Bowen T, Cicardi M, Farkas H, et al: 2010 International consensus algorithm for the diagnosis, therapy and management of hereditary angioedema. Allergy Asthma Clin Immunol 2010;6:24
20. Zuraw BL: HAE therapies: Past present and future. Allergy Asthma Clin Immunol 2010;6:23
21. Schmidt W, Stenzel K, Gebhard MM, et al: C1-esterase inhibitor and its effects on endotoxininduced leukocyte adherence and plasma extravasation in postcapillary venules. Surgery 1999;125:280-287
22. Wagner E, Frank MM: Therapeutic potential of complement modulation. Nat Rev Drug Discov 2010;9:43-56